全文获取类型
收费全文 | 345302篇 |
免费 | 23578篇 |
国内免费 | 7367篇 |
专业分类
耳鼻咽喉 | 4182篇 |
儿科学 | 9829篇 |
妇产科学 | 6729篇 |
基础医学 | 27574篇 |
口腔科学 | 8224篇 |
临床医学 | 38272篇 |
内科学 | 42628篇 |
皮肤病学 | 4718篇 |
神经病学 | 19418篇 |
特种医学 | 8401篇 |
外国民族医学 | 31篇 |
外科学 | 36852篇 |
综合类 | 52322篇 |
现状与发展 | 12篇 |
一般理论 | 30篇 |
预防医学 | 36073篇 |
眼科学 | 5462篇 |
药学 | 30774篇 |
415篇 | |
中国医学 | 30540篇 |
肿瘤学 | 13761篇 |
出版年
2023年 | 5396篇 |
2022年 | 8056篇 |
2021年 | 12884篇 |
2020年 | 12686篇 |
2019年 | 18496篇 |
2018年 | 16252篇 |
2017年 | 13081篇 |
2016年 | 10538篇 |
2015年 | 9876篇 |
2014年 | 20563篇 |
2013年 | 21973篇 |
2012年 | 18819篇 |
2011年 | 20301篇 |
2010年 | 16298篇 |
2009年 | 14954篇 |
2008年 | 14590篇 |
2007年 | 15060篇 |
2006年 | 13111篇 |
2005年 | 11358篇 |
2004年 | 9242篇 |
2003年 | 8100篇 |
2002年 | 6326篇 |
2001年 | 5682篇 |
2000年 | 4689篇 |
1999年 | 4059篇 |
1998年 | 3097篇 |
1997年 | 2962篇 |
1996年 | 2548篇 |
1995年 | 2627篇 |
1994年 | 2532篇 |
1993年 | 2035篇 |
1992年 | 2038篇 |
1991年 | 1770篇 |
1990年 | 1573篇 |
1989年 | 1397篇 |
1988年 | 1323篇 |
1987年 | 1134篇 |
1985年 | 3828篇 |
1984年 | 4843篇 |
1983年 | 3373篇 |
1982年 | 3866篇 |
1981年 | 3577篇 |
1980年 | 3197篇 |
1979年 | 2946篇 |
1978年 | 2560篇 |
1977年 | 1935篇 |
1976年 | 2171篇 |
1975年 | 1656篇 |
1974年 | 1445篇 |
1973年 | 1289篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
《The British journal of oral & maxillofacial surgery》2022,60(2):183-189
Trismus is one of the most debilitating and treatment-resistant complications resulting from head and neck oncological treatments. The objective of this study was to assess how primary tumour variables could assist in predicting chronic trismus. From a (retrospective) oncological database (Department of Oral and Maxillofacial Surgery, University Hospitals Leuven), tumour-related, surgical, and oral functional variables were reviewed. Contributing factors for chronic trismus, defined as a mouth opening of less than 35 mm, at least one year after treatment for oral squamous cell cancer, were assessed via logistic regression. A mediational analysis was conducted on the significant predictive variables. Thirteen out of 52 patients were observed to have chronic trismus. A significantly higher prevalence of trismus was found for increasing clinical T classification (p < 0.01), tumours based in the maxilla or the retromolar trigone (p = 0.04), after adjuvant radiotherapy (p = 0.04), and/or with masticatory muscle tumour invasion (p ≤ 0.02). Furthermore, radiotherapy significantly impacted T classification in chronic trismus, while T classification was significantly related to masticatory muscle invasion. Although radiotherapy and clinical T classification are well-established risk factors for postoperative trismus, masticatory muscle invasion should be considered as one of the main predictive factors. 相似文献
102.
103.
《Ophthalmology》2023,130(8):844-853
104.
105.
Loren Saulsberry PhD Ankur Bhargava MD MPH Sharon Zeng BA Jason B. Gibbons PhD Cody Brannan MS Diane S. Lauderdale PhD Robert D. Gibbons PhD 《Health services research》2023,58(4):873-881
Objective
To derive and validate a new ecological measure of the social determinants of health (SDoH), calculable at the zip code or county level.Data Sources and Study Setting
The most recent releases of secondary, publicly available data were collected from national U.S. health agencies as well as state and city public health departments.Study Design
The Social Vulnerability Metric (SVM) was constructed from U.S. zip-code level measures (2018) from survey data using multidimensional Item Response Theory and validated using outcomes including all-cause mortality (2016), COVID-19 vaccination (2021), and emergency department visits for asthma (2018). The SVM was also compared with the existing Centers for Disease Control and Prevention's Social Vulnerability Index (SVI) to determine convergent validity and differential predictive validity.Data Collection/Extraction Methods
The data were collected directly from published files available to the public online from national U.S. health agencies as well as state and city public health departments.Principal Findings
The correlation between SVM scores and national age-adjusted county all-cause mortality was r = 0.68. This correlation demonstrated the SVM's robust validity and outperformed the SVI with an almost four-fold increase in explained variance (46% vs. 12%). The SVM was also highly correlated (r ≥ 0.60) to zip-code level health outcomes for the state of California and city of Chicago.Conclusions
The SVM offers a measurement tool improving upon the performance of existing SDoH composite measures and has broad applicability to public health that may help in directing future policies and interventions. The SVM provides a single measure of SDoH that better quantifies associations with health outcomes. 相似文献106.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
107.
《Drug discovery today》2022,27(5):1367-1380
The tremendous advances in genomics, recombinant DNA technology, bioengineering and nanotechnology, in conjunction with the development of high-end computations, have been instrumental in the process of rational design of peptide-based vaccines. The use of peptide vaccines was limited owing to their inherent instability when systemically administered; however, advanced formulation techniques have been developed for their systemic delivery, thereby overcoming their degradation, clearance, cellular uptake and off-target effects. With the rise of sophisticated immunological predictors and experimental techniques, several methodological advances have occurred in this field. This review examines contemporary methods to identify and optimize epitopes, engineer their immunogenic properties and develop their safe and efficient delivery into the host. 相似文献
108.
109.
《The Journal for Nurse Practitioners》2022,18(3):285-288
Child sex trafficking (CST) has become a global public health crisis and is a $150 billion criminal enterprise. Nurse practitioners are key in the recognition and prevention of CST in health care settings. Evidence demonstrates that up to 80% of CST victims have had a recent health care encounter. It is the role of the NP in practice to understand risk factors, screen for CST, and educate parents and caregivers on signs of victimization and prevention. 相似文献
110.
《Vaccine》2022,40(24):3380-3388
BackgroundWe evaluated the safety and immunogenicity of NVX-CoV2373, a recombinant SARS-CoV-2 nanoparticle vaccine, in healthy Japanese participants.MethodsThis phase 1/2, randomized, observer-blind, placebo-controlled trial conducted in Japan (two sites), enrolled healthy Japanese adults aged ≥ 20 years with no history/risk of SARS-CoV-2 infection and no prior exposure to other approved/investigational SARS-CoV-2 vaccines or treatments. Participants were stratified by age (< 65 or ≥ 65 years) and randomized to receive two doses of either NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1) or placebo, 21 days apart. Primary outcomes were safety and immunogenicity assessed by serum IgG antibody levels against SARS-CoV-2 rS protein on day 36. Herein, we report the primary data analysis at 4 weeks after the second dose, ahead of 12-month follow-up completion (data cut-off: 8 May 2021).ResultsBetween 12 February 2021 and 17 March 2021, 326 subjects were screened, and 200 participants enrolled and randomized: NVX-CoV2373, n = 150; placebo, n = 50. Solicited adverse events (AEs) through 7 days after each injection occurred in 121/150 (80.7%) and 11/50 (22.0%) participants in the NVX-CoV2373 and placebo arms, respectively. In the NVX-CoV2373 arm, tenderness and injection site pain were the most frequently reported solicited AEs after each vaccination, irrespective of age. Robust immune responses occurred with NVX-CoV2373 (n = 150) by day 36: IgG geometric mean fold rise (95% confidence interval) 259 (219, 306); seroconversion rate 100% (97.6, 100). No such response occurred with placebo (n = 49).ConclusionTwo doses of NVX-CoV2373 given with a 21-day interval demonstrated acceptable safety and induced robust anti-SARS-CoV-2 immune responses in healthy Japanese adults. Funding: Takeda Pharmaceutical Company Limited and Japan Agency for Medical Research and Development (AMED). ClinicalTrials.gov identifier: NCT04712110. 相似文献